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Analysis of the clinical phenotype: history, examination and investigation, is the physician's 
daily work1. Documentation of patient phenotypes has become particularly to clarify 
genotype–phenotype relationships that are increasingly being investigated by the use of high 
throughput molecular technologies. To improve the clinical utility of emerging -omics 
technologies, such as next generation sequencing, there is a parallel and increasing need for 
efficient, and preferably objective and standardised, documentation of the clinical phenotype. 
This will require time-efficient tools for ascertaining phenotypic information, incorporating 
this information into clinical work flows, and for integrating with -omics analyses. This 
presentation will focus on aspects of phenotyping that are of particular relevance to rare 
diseases and which have implications for common diseases. Firstly, for illustrative purposes, 
it will discuss 3-dimensional facial analysis: a fine scale, objective, scalable, portable, cost 
efficient, non-invasive and non-irradiating phenotypic assessment2. Secondly, it will describe 
the “4th dimension” of bed-side capture of standardized phenotypic information, workflow 
integration and emerging decision support tools. 
Robinson PN. 2012. Deep phenotyping for precision medicine. Hum Mutat 33(5):777–780  
Baynam G, Walters M, Claes P, Kung S, LeSouef P, Dawkins H, Gillett D, Goldblatt J. 2013. 
The facial evolution: looking backward and moving forward. Hum Mutat 34(1):14–22  
 
